Paul Richardson, Dana-Farber Cancer Institute (IMAGE)

Dana-Farber Cancer Institute

Paul Richardson, Dana-Farber Cancer Institute

Caption

In a study led by Paul Richardson, MD, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.